porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2015220-24porozendo-8911Research ArticleСтатьиArticlesАКТУАЛЬНОСТЬ, ПРЕИМУЩЕСТВА И КЛИНИЧЕСКИЕ ПЕРСПЕКТИВЫ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ ОСТЕОПОРОЗА НА ОСНОВЕ КОСТНО-АНАБОЛИЧЕСКОй ТЕРАПИИTHE RELEVANCE, BENEFITS AND CLINICAL PERSPECTIVES OF THE COMBINED TREATMENT OF OSTEOPOROSIS BASED ON BONE-ANABOLIC THERAPYМарченковаЛ АMarchenkovaL A

зав. отделом активного долголетия и эндокринологии к.м.н.

lr-march@rambler.ruМартыноваМ ЮMartynovaE Yu

младший научный сотрудник отдела активного долголетия и эндокринологии

-ФГБУ «Российский научный центр медицинской реабилитации и курортологии» Минздрава России201515122015182№2 (2015)2024Copyright © Марченкова Л.А., Мартынова М.Ю., 20152015Марченкова Л.А., Мартынова М.Ю.Marchenkova L.A., Martynova E.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/8911

Комбинированная терапия остеопороза, основанная на применении костно-анаболических и антирезорбтивных препаратов, имеет большие перспективы. Анализ литературы показывает, что основной целью использования комбинаций препаратов с различным механизмом действия является повышение эффективности лечения. Комбинированная терапия может быть представлена как одновременным применением терипаратида с деносумабом, ралоксифе-ном или с гормональной терапией, так и последовательным назначением деносумаба, ралоксифена или бисфосфонтов после курса лечения терипаратидом. обзор представляет доказательную базу в отношении эффективности одновременной или последовательной комбинированной терапии, в отношении динамики МПК и снижения риска остеопоро-тических переломов.

Combination therapy of osteoporosis based on bone-anabolic and antiresorbtive agents has a great clinical perspective. An analysis of available publications shows that combination therapy is appropriate from the standpoint of increasing the effectiveness of treatment. Combination therapy can be executed as a simultaneous use of teriparatide with denosumab, raloxifene or hormonal therapy, and the subsequent administration of bisphosphonates, denosumab or raloxifene after treatment with teriparatide. The review presents the evidence-based data on the effect of combined and sequential regimens for osteoporosis fracture risk.

остеопорозтерипаратидкомбинированная терапияпоследовательная терапияosteoporosisteriparatidethe combination therapysequential therapydenosumabraloxifenehormone replacement therapybisphosphonatesReferencesЛесняк О.М. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии. Остеопо-роз и Остеопатии.Лесняк О.М. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии. Остеопо-роз и Остеопатии.Lecart M.-P., Bruyere O., Reginster J.-Y. Combination/ sequential therapy in osteoporosis. Curr Osteoporos Rep. 2004; 2(4): 123-130. http: //www.ncbi.nlm.nih.gov/pubmed/16036093.Lecart M.-P., Bruyere O., Reginster J.-Y. Combination/ sequential therapy in osteoporosis. Curr Osteoporos Rep. 2004; 2(4): 123-130. http: //www.ncbi.nlm.nih.gov/pubmed/16036093.Howard E., Tagliarino-Jones H. FPIN’s clinical inquiries. Combination therapy for postmenopausal osteoporosis. Am Fam Physician. 2010; 81(4): 439. http: //www.ncbi.nlm.nih.gov/ pubmed/20148496.Howard E., Tagliarino-Jones H. FPIN’s clinical inquiries. Combination therapy for postmenopausal osteoporosis. Am Fam Physician. 2010; 81(4): 439. http: //www.ncbi.nlm.nih.gov/ pubmed/20148496.Boonen S., Vanderschueren D., Haentjens P., Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med. 2006; 259(6): 539-552. doi: 10.1111/j.1365-2796.2006.01655.x.Boonen S., Vanderschueren D., Haentjens P., Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med. 2006; 259(6): 539-552. doi: 10.1111/j.1365-2796.2006.01655.x.Cosman F. Combination therapy for osteoporosis: a reappraisal. Bonekey Rep. 2014; 3: 518. doi: 10.1038/bonekey. 2014.13.Cosman F. Combination therapy for osteoporosis: a reappraisal. Bonekey Rep. 2014; 3: 518. doi: 10.1038/bonekey. 2014.13.Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104(4): 439-446. doi: 10.1172/JCI6610.Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104(4): 439-446. doi: 10.1172/JCI6610.Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993; 14(6): 690-709. doi: 10.1210/edrv-14-6-690.Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993; 14(6): 690-709. doi: 10.1210/edrv-14-6-690.Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19): 1434-1441. doi: 10.1056/NEJM200105103441904.Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19): 1434-1441. doi: 10.1056/NEJM200105103441904.McClung M.R., San Martin J., Miller P.D., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 165(15): 1762-1768. doi: 10.1001/archinte.165.15.1762.McClung M.R., San Martin J., Miller P.D., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 165(15): 1762-1768. doi: 10.1001/archinte.165.15.1762.Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.-Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006; 22(1): 61-66. doi: 10.1185/030079905X75096.Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.-Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006; 22(1): 61-66. doi: 10.1185/030079905X75096.Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (134) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18(11): 1932-1941. doi: 10.1359/jbmr.2003.18.11.1932.Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (134) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18(11): 1932-1941. doi: 10.1359/jbmr.2003.18.11.1932.Compston J. The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine. 2012; 41(1): 11-18. doi: 10.1007/s12020-011-9554-2.Compston J. The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine. 2012; 41(1): 11-18. doi: 10.1007/s12020-011-9554-2.Ste-Marie L.G., Schwartz S.L., Hossain A., Desaiah D., Gaich G.A. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res. 2006; 21(2): 283-291. doi: 10.1359/JBMR.051020.Ste-Marie L.G., Schwartz S.L., Hossain A., Desaiah D., Gaich G.A. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res. 2006; 21(2): 283-291. doi: 10.1359/JBMR.051020.Cosman F., Nieves J., Woelfert L., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16(5): 925-931. doi: 10.1359/jbmr.2001.16.5.925.Cosman F., Nieves J., Woelfert L., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16(5): 925-931. doi: 10.1359/jbmr.2001.16.5.925.Leder B.Z., Tsai J.N., Uihlein A.V., et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (London, England). 2015; 386(9999): 1147-1155. doi: 10.1016/S0140-6736(15)61120-5.Leder B.Z., Tsai J.N., Uihlein A.V., et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (London, England). 2015; 386(9999): 1147-1155. doi: 10.1016/S0140-6736(15)61120-5.Leder B.Z., Tsai J.N., Uihlein A.V., et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014; 99(5): 1694-1700. doi: 10.1210/jc.2013-4440.Leder B.Z., Tsai J.N., Uihlein A.V., et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014; 99(5): 1694-1700. doi: 10.1210/jc.2013-4440.Tsai J.N., Uihlein A.V., Lee H., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (London, England). 2013; 382(9886): 50-56. doi: 10.1016/S0140-6736(13)60856-9.Tsai J.N., Uihlein A.V., Lee H., et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (London, England). 2013; 382(9886): 50-56. doi: 10.1016/S0140-6736(13)60856-9.Tsai J.N., Uihlein A.V., Burnett-Bowie S.-AM., et al. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res. 2015; 30(1): 39-45. doi: 10.1002/jbmr.2315.Tsai J.N., Uihlein A.V., Burnett-Bowie S.-AM., et al. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res. 2015; 30(1): 39-45. doi: 10.1002/jbmr.2315.Deal C., Omizo M., Schwartz E.N., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005; 20(11): 1905-1911. doi: 10.1359/JBMR.050714.Deal C., Omizo M., Schwartz E.N., et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005; 20(11): 1905-1911. doi: 10.1359/JBMR.050714.Prince R., Sipos A., Hossain A., et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005; 20(9): 1507-1513. doi: 10.1359/JBMR.050501.Prince R., Sipos A., Hossain A., et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005; 20(9): 1507-1513. doi: 10.1359/JBMR.050501.Deal C., Tuthill K., Kriegman A. Zoledronic acid after 2-years of teriparatide: bone density and bone turnover markers in 35 patients. Arthritis Rheum 2009; 60: 885. http: //www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=761&id=80515.Deal C., Tuthill K., Kriegman A. Zoledronic acid after 2-years of teriparatide: bone density and bone turnover markers in 35 patients. Arthritis Rheum 2009; 60: 885. http: //www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=761&id=80515.Abrahamsen B. Bone: Sequential osteoporosis treatment-the order of things. Nat Rev Endocrinol. 2015; 11(10): 570-572. doi: 10.1038/nrendo.2015.134.Abrahamsen B. Bone: Sequential osteoporosis treatment-the order of things. Nat Rev Endocrinol. 2015; 11(10): 570-572. doi: 10.1038/nrendo.2015.134.Adami S., San Martin J., Munoz-Torres M., et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008; 19(1): 87-94. doi: 10.1007/s00198-007-0485-y.Adami S., San Martin J., Munoz-Torres M., et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008; 19(1): 87-94. doi: 10.1007/s00198-007-0485-y.Eastell R., Nickelsen T., Marin F., et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009; 24(4): 726-736. doi: 10.1359/jbmr.081215.Eastell R., Nickelsen T., Marin F., et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009; 24(4): 726-736. doi: 10.1359/jbmr.081215.Anastasilakis A.D., Polyzos S.A., Avramidis A., Papatheodorou A., Terpos E. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res. 2009; 41(7): 559-562. doi: 10.1055/s-0029-1192035.Anastasilakis A.D., Polyzos S.A., Avramidis A., Papatheodorou A., Terpos E. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res. 2009; 41(7): 559-562. doi: 10.1055/s-0029-1192035.Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19(5): 745-751. doi: 10.1359/JBMR.040117.Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19(5): 745-751. doi: 10.1359/JBMR.040117.Misof B.M., Paschalis E.P., Blouin S., Fratzl-Zelman N., Klaushofer K., Roschger P. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res. 2010; 25(11): 2297-2303. doi: 10.1002/jbmr.198.Misof B.M., Paschalis E.P., Blouin S., Fratzl-Zelman N., Klaushofer K., Roschger P. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate. J Bone Miner Res. 2010; 25(11): 2297-2303. doi: 10.1002/jbmr.198.Jakob F., Oertel H., Langdahl B., et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol. 2012; 166(1): 87-97. doi: 10.1530/EJE-11-0740.Jakob F., Oertel H., Langdahl B., et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol. 2012; 166(1): 87-97. doi: 10.1530/EJE-11-0740.Song J., Jin Z., Chang F., Li L., Su Y. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs. Med Sci Monit. 2014; 20: 2624-2632. doi: 10.12659/MSM.892581.Song J., Jin Z., Chang F., Li L., Su Y. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs. Med Sci Monit. 2014; 20: 2624-2632. doi: 10.12659/MSM.892581.Finkelstein J.S., Wyland J.J., Lee H., Neer R.M. Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2010; 95(4): 1838-1845. doi: 10.1210/jc.2009-1703.Finkelstein J.S., Wyland J.J., Lee H., Neer R.M. Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2010; 95(4): 1838-1845. doi: 10.1210/jc.2009-1703.Cosman F., Nieves J.W., Zion M., et al. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. J Clin Endocrinol Metab. 2015; 100(7): 2769-2776. doi: 10.1210/jc.2015-1715.Cosman F., Nieves J.W., Zion M., et al. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. J Clin Endocrinol Metab. 2015; 100(7): 2769-2776. doi: 10.1210/jc.2015-1715.

The authors declare that there are no conflicts of interest present.